SBI Life Insurance Company Ltd

Meeting Details

• Date: August 27, 2026
• Time: not disclosed
• Type and mode: group in-person meeting
• Event/organiser: Morgan Stanley - India Financials Investor Group Trip
• Location: Mumbai

Participants

• Senior management participants from SBI Life

Purpose

• Senior management to interact with investor(s)/analyst(s)

Cessation of Independent Director

• Narayan K. Seshadri, Independent Director, ceases on completion of two three-year terms, Aug 19, 2026.

Key results & regulatory notes

• Board approves Q1 FY27 unaudited results for quarter ended June 30, 2026.
• Results prepared under Indian GAAP due to IRDAI forbearance to defer Ind AS adoption.
• IRDAI forbearance permits Ind AS transition deferment for FY2026-27; results published per GAAP.
• Independent auditors issued unmodified limited review.
• Company allotted 148,413 equity shares under ESOS 2018 in the quarter.
• Solvency ratio at 1.96x as of June 30, 2026, up from 1.90x prior period.
• Earnings per share: Basic 7.23, Diluted 7.22 for the quarter.
• Embedded value as at 30 Jun 2026: ₹852.9 billion; three-month new business value: ₹14.1 billion.
• Willis Towers Watson review confirms methodology compliant; no material issues.
• Results to be published on SBI Life website by August 14, 2026.

AGM Details

• Board approves 26th AGM on Friday, Aug 14, 2026 at 02:30 PM IST via VC/OAVM.
• Board meeting to approve AGM ran from 05:00 PM to 06:00 PM IST.

ESOS grant details

• Instrument: Employee stock options (ESOS) under ESOS-2018, exercisable into equity shares.
• Total options granted: 8,94,910 to eligible employees.
• Underlying shares: one equity share of Rs 10 on exercise.
• Exercise price: lower of grant-date FMV or 15-day average FMV.
• Vesting: 30% after year 1, then 30%, then 40%.
• Vesting commencement: from one year from grant date.
• Exercise window: seven years from grant date.
• Allottees: eligible employees; group unspecified.
• Post-issue shareholding: not disclosed.
• Approval: Board Nomination and Remuneration Committee approved on July 13, 2026.
• Scheme/Par value: ESOS-2018; face value Rs 10 per share.

Dematerialisation status

• All SBI Life securities are held in dematerialised form; no rematerialisation requests were received.
• Regulation 74(5) requirements are not applicable for the quarter ended June 30, 2026.

Meeting Details

• Board meeting scheduled for Friday, July 24, 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve financial results for the quarter ended June 30, 2026.

Other Notes

• Trading window closes from July 1, 2026 and reopens 48 hours after results declaration.